Securing IoT Attacks: A Machine Learning Approach for Developing Lightweight Trust-Based Intrusion Detection System

The routing process in the Internet of Things (IoT) presents challenges in industrial applications due to its complexity, involving multiple devices, critical decision-making, and accurate data transmission. The complexity further increases with dynamic IoT devices, which creates opportunities for potential intruders to disrupt routing. Traditional security measures are inadequate for IoT devices with limited battery capabilities. Although RPL (Routing Protocol for Low Energy and Lossy Networks) is commonly used for IoT routing, it remains vulnerable to security threats. This study aims to detect and isolate three routing attacks on RPL: Rank, Sybil, and Wormhole. To achieve this, a lightweight trust-based secured routing system is proposed, utilizing machine learning techniques to derive values for devices in new networks, where initial trust values are unavailable. The system demonstrates successful detection and isolation of attacks, achieving an accuracy of 98.59%, precision of 98%, recall of 99%, and f-score of 98%, thereby reinforcing its effectiveness. Attacker nodes are identified and promptly disabled, ensuring a secure routing environment. Validation on a generated dataset further confirms the reliability of the system

Giant angioleiomyoma of uterus masquerading as ovarian tumour: a case report

Angioleiomyoma is a rare benign tumour of uterus. We are presenting an unusual case of 45-year-old female with 11 kg giant angioleiomyoma of uterus which was masquerading as ovarian tumour on imaging. Exploratory laparotomy was done which was suggestive of huge lobulated mass arising from the uterus. Hysterectomy with bilateral salpingo-oophorectomy was done. Histopathological examination of specimen was suggestive of uterine subserosal and broad ligament angioleiomyoma of cavernous type. This case is being reported because of its rarity and challenges in diagnosis and management

Cassandra File System Over Hadoop Distributed File System

Cassandra is an open source distributed database management system is designed to handle large amounts of data across many commodity servers, provides a high availability with no single point of failure. Cassandra will be offering the robust support for clusters spanning multiple data centers with asynchronous masterless replica which allow low latency operations for all the clients. N oSQL data stores target the unstructured data, which nature has dynamic and a key focus area for "Big Data" research. New generation data can prove costly and also unpractical to administer with databases SQL, due to lack of structure, high scalability and needs for the elasticity. N oSQL data stores such as MongoDB and Cassandra provide a desirable platform for fast and efficient for data queries. The Hadoop Distributed File System is one of many different components and projects contained within the community Hadoop ecosystem. The Apache Hadoop project defines Had oop - DFS as "the primary storage system which is used by Hadoop applications" that enables "reliable, extremely rapid computations". This paper was providing high - level overview of how Hadoop - styled analytics (MapReduce, Pig, Mahout and Hive) can be run on data contained in Apache Cassandra wit hout the need for Hadoop - DFS

Anti-Inflammatory Activity of Delonix regia (Boj. Ex. Hook)

The present work was to evaluate the anti-inflammatory activity of Delonix regia leaves (Family: Caesalpiniaceae). The powder of Delonix regia leaves was subjected to extraction with ethanol in soxhlet extractor. The ethanol extract after preliminary phytochemical investigation showed the presence of sterols, triterpenoids, phenolic compounds and flavonoids. The anti-inflammatory activity was studied using carrageenan-induced rat paw edema and cotton pellet granuloma at a three different doses (100, 200, and 400 mg/kg b.w. p.o.) of ethanol extract. The ethanol extract of Delonix regia leaves was exhibited significant anti-inflammatory activity at the dose of 400 mg/kg in both models when compared with control group. Indomethacin (10 mg/kg b.w. p.o) was also shown significant anti-inflammatory activity in both models

Experimental study of effect of pressure on pyrolysis of biomass

Pyrolysis is thermal treatment of solid waste in the absence of an oxidizing agent (in inert atmosphere) which generally yields three products namely pyrolysis-oil (liquid), char (solid residue) and gas. The products obtained in pyrolysis can be further used as energy source. Rice husk and saw dust are considered as solid wastes in this study. The effect of temperature and pressure on pyrolysis was studied in a fixed bed reactor. The experimental runs were performed in nitrogen atmosphere. The temperature was varied from 300°C to 500°C, while the operational pressure was fixed at 4 bar, 7 bar and 10 bar. The products such as solid char, liquid pyrolysis oil and syngas were obtained. The solid char was characterized by CHNS analysis, while the pyrolysis oil was characterized by FTIR analysis

Phytochemical investigation and anti-Inflammatory activity of Coccinia indica wight and arn. (Cucurbitaceae) fruits

The present work was to study the anti-inflammatory activity of Coccinia indica Wight and Arn fruits belonging to family Cucurbitaceae. The fruit powder of C. indica was subjected to successive extraction with petroleum ether, chloroform, ethanol and water in a Soxhlet extractor. The ethanol extract after preliminary phytochemical investigation shown the presence of glycosides, triterpenoids, flavonoids, tannins and phenolic compounds. The anti-inflammatory activity was studied using carrageenan-induced rat paw oedema and cotton pellet granuloma at three different doses (100, 200 and 400 mg/kg b.w. p.o.) of each extract. The ethanol extract of C. indica fruits exhibited significant anti-inflammatory activity at the dose of 200 mg/kg and 400 mg/kg in both models when compared with control group. Indomethacin (10 mg/kg b.w. p.o) also showed significant anti-inflammatory activity in both models.Colegio de Farmacéuticos de la Provincia de Buenos Aire

Molecular insights into Coumarin analogues as antimicrobial agents: Recent developments in drug discovery

A major global health risk has been witnessed with the development of drug-resistant bacteria and multidrug-resistant pathogens linked to significant mortality. Coumarins are heterocyclic compounds belonging to the benzophenone class enriched in different plants. Coumarins and their derivatives have a wide range of biological activity, including antibacterial, anticoagulant, antioxidant, anti-inflammatory, antiviral, antitumour, and enzyme inhibitory effects. In the past few years, attempts have been reported towards the optimization, synthesis, and evaluation of novel coumarin analogues as antimicrobial agents. Several coumarin-based antibiotic hybrids have been developed, and the majority of them were reported to exhibit potential antibacterial effects. In the present work, studies reported from 2016 to 2020 about antimicrobial coumarin analogues are the focus. The diverse biological spectrum of coumarins can be attributed to their free radical scavenging abilities. In addition to various synthetic strategies developed, some of the structural features include a heterocyclic ring with electron-withdrawing/donating groups conjugated with the coumarin nucleus. The suggested structure−activity relationship (SAR) can provide insight into how coumarin hybrids can be rationally improved against multidrug-resistant bacteria. The present work demonstrates molecular insights for coumarin derivatives having antimicrobial properties from the recent past. The detailed SAR outcomes will benefit towards leading optimization during the discovery and development of novel antimicrobial therapeutics

A Practitioner’s Toolkit for Insulin Motivation in Adults with Type 1 and Type 2 Diabetes Mellitus: Evidence-Based Recommendations from an International Expert Panel

Aim To develop an evidence-based expert group opinion on the role of insulin motivation to overcome insulin distress during different stages of insulin therapy and to propose a practitioner’s toolkit for insulin motivation in the management of diabetes mellitus (DM). Background Insulin distress, an emotional response of the patient to the suggested use of insulin, acts as a major barrier to insulin therapy in the management of DM. Addressing patient-, physician- and drug-related factors is important to overcome insulin distress. Strengthening of communication between physicians and patients with diabetes and enhancing the patients' coping skills are prerequisites to create a sense of comfort with the use of insulin. Insulin motivation is key to achieving targeted goals in diabetes care. A group of endocrinologists came together at an international meeting held in India to develop tool kits that would aid a practitioner in implementing insulin motivation strategies at different stages of the journey through insulin therapy, including pre-initiation, initiation, titration and intensification. During the meeting, emphasis was placed on the challenges and limitations faced by both physicians and patients with diabetes during each stage of the journey through insulinization. Review Results After review of evidence and discussions, the expert group provided recommendations on strategies for improved insulin acceptance, empowering behavior change in patients with DM, approaches for motivating patients to initiate and maintain insulin therapy and best practices for insulin motivation at the pre-initiation, initiation, titration and intensification stages of insulin therapy. Conclusions In the management of DM, bringing in positive behavioral change by motivating the patient to improve treatment adherence helps overcome insulin distress and achieve treatment goals

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Background: Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. Methods: In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post-baseline assessment. The trial was conducted at 191 clinical research sites in 27 countries and is registered with ClinicalTrials.gov, number NCT01272219. Findings: The study ran between June 1, 2011, and March 2, 2015. We randomly assigned 2254 patients to receive liraglutide (n=1505) or placebo (n=749). 1128 (50%) participants completed the study up to week 160, after withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the placebo group. By week 160, 26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on treatment. The mean time from randomisation to diagnosis was 99 (SD 47) weeks for the 26 individuals in the liraglutide group versus 87 (47) weeks for the 46 individuals in the placebo group. Taking the different diagnosis frequencies between the treatment groups into account, the time to onset of diabetes over 160 weeks among all randomised individuals was 2·7 times longer with liraglutide than with placebo (95% CI 1·9 to 3·9, p<0·0001), corresponding with a hazard ratio of 0·21 (95% CI 0·13–0·34). Liraglutide induced greater weight loss than placebo at week 160 (–6·1 [SD 7·3] vs −1·9% [6·3]; estimated treatment difference −4·3%, 95% CI −4·9 to −3·7, p<0·0001). Serious adverse events were reported by 227 (15%) of 1501 randomised treated individuals in the liraglutide group versus 96 (13%) of 747 individuals in the placebo group. Interpretation: In this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals were not followed up after discontinuation. Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes. Funding: Novo Nordisk, Denmark

Neurodevelopmental disorders in children aged 2-9 years: Population-based burden estimates across five regions in India.

BACKGROUND: Neurodevelopmental disorders (NDDs) compromise the development and attainment of full social and economic potential at individual, family, community, and country levels. Paucity of data on NDDs slows down policy and programmatic action in most developing countries despite perceived high burden. METHODS AND FINDINGS: We assessed 3,964 children (with almost equal number of boys and girls distributed in 2-<6 and 6-9 year age categories) identified from five geographically diverse populations in India using cluster sampling technique (probability proportionate to population size). These were from the North-Central, i.e., Palwal (N = 998; all rural, 16.4% non-Hindu, 25.3% from scheduled caste/tribe [SC-ST] [these are considered underserved communities who are eligible for affirmative action]); North, i.e., Kangra (N = 997; 91.6% rural, 3.7% non-Hindu, 25.3% SC-ST); East, i.e., Dhenkanal (N = 981; 89.8% rural, 1.2% non-Hindu, 38.0% SC-ST); South, i.e., Hyderabad (N = 495; all urban, 25.7% non-Hindu, 27.3% SC-ST) and West, i.e., North Goa (N = 493; 68.0% rural, 11.4% non-Hindu, 18.5% SC-ST). All children were assessed for vision impairment (VI), epilepsy (Epi), neuromotor impairments including cerebral palsy (NMI-CP), hearing impairment (HI), speech and language disorders, autism spectrum disorders (ASDs), and intellectual disability (ID). Furthermore, 6-9-year-old children were also assessed for attention deficit hyperactivity disorder (ADHD) and learning disorders (LDs). We standardized sample characteristics as per Census of India 2011 to arrive at district level and all-sites-pooled estimates. Site-specific prevalence of any of seven NDDs in 2-<6 year olds ranged from 2.9% (95% CI 1.6-5.5) to 18.7% (95% CI 14.7-23.6), and for any of nine NDDs in the 6-9-year-old children, from 6.5% (95% CI 4.6-9.1) to 18.5% (95% CI 15.3-22.3). Two or more NDDs were present in 0.4% (95% CI 0.1-1.7) to 4.3% (95% CI 2.2-8.2) in the younger age category and 0.7% (95% CI 0.2-2.0) to 5.3% (95% CI 3.3-8.2) in the older age category. All-site-pooled estimates for NDDs were 9.2% (95% CI 7.5-11.2) and 13.6% (95% CI 11.3-16.2) in children of 2-<6 and 6-9 year age categories, respectively, without significant difference according to gender, rural/urban residence, or religion; almost one-fifth of these children had more than one NDD. The pooled estimates for prevalence increased by up to three percentage points when these were adjusted for national rates of stunting or low birth weight (LBW). HI, ID, speech and language disorders, Epi, and LDs were the common NDDs across sites. Upon risk modelling, noninstitutional delivery, history of perinatal asphyxia, neonatal illness, postnatal neurological/brain infections, stunting, LBW/prematurity, and older age category (6-9 year) were significantly associated with NDDs. The study sample was underrepresentative of stunting and LBW and had a 15.6% refusal. These factors could be contributing to underestimation of the true NDD burden in our population. CONCLUSIONS: The study identifies NDDs in children aged 2-9 years as a significant public health burden for India. HI was higher than and ASD prevalence comparable to the published global literature. Most risk factors of NDDs were modifiable and amenable to public health interventions